Novavax Inc said on Wednesday it has entered a supply and license agreement with the Serum Institute of India for the development and commercialization of its COVID-19 vaccine candidate.
The Indian drugmaker will have exclusive rights for the vaccine in India during the term of the deal and non-exclusive rights during the “Pandemic Period” in all countries other than those designated by the World Bank as upper-middle or high-income countries.
The deal was signed on July 30, according to an SEC filing by Novavax. https://bit.ly/3iggGQv
Flooding In Mumbai As The City Records Heaviest Rainfall Since 2005
On Tuesday, Novavax reported that its experimental COVID-19 vaccine produced high levels of antibodies against the novel coronavirus in a small, early-stage clinical trial, and that it could start a large pivotal Phase III trial as soon as late September.
Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor
[videos] => Array
 => Array
[id] => 5f2af7dccc17de12942f2b32
[youtube_id] => Vh8512tXzC0
Novavax signs COVID-19 vaccine supply deal with India’s Serum Institute => Flooding In Mumbai As The City Records Heaviest Rainfall Since 2005
 => Array
[id] => 5f2aed89db1d45129a3486b5
[youtube_id] => _NugDbuNiNA
Novavax signs COVID-19 vaccine supply deal with India’s Serum Institute => Disha Salian’s Post-Mortem Report Reveals Another Twist In Sushant’s Death Probe | News Epicentre